Abstract
TRPV1 has emerged as a promising therapeutic target for pain as well as a broad range of other conditions such as asthma or urge incontinence. The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation. While agonism and antagonism have represented the primary directions for drug development, the pharmacological complexity of TRPV1 affords additional opportunities. Partial agonism/partial antagonism, its modulation by signaling pathways, variable desensitization, and slow kinetics of action can all be exploited through drug design.
Keywords: Resiniferatoxin, capsaicin, partial agonist, partial antagonist, TRPV1, efficacy, signaling pathway, asthma or urge incontinence, activation of TRPV1, subsequent desensitization, pharmacological manipulation, agonism and antagonism, slow kinetics of action, drug design
Current Topics in Medicinal Chemistry
Title: TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation
Volume: 11 Issue: 17
Author(s): Peter M. Blumberg, Larry V. Pearce and Jeewoo Lee
Affiliation:
Keywords: Resiniferatoxin, capsaicin, partial agonist, partial antagonist, TRPV1, efficacy, signaling pathway, asthma or urge incontinence, activation of TRPV1, subsequent desensitization, pharmacological manipulation, agonism and antagonism, slow kinetics of action, drug design
Abstract: TRPV1 has emerged as a promising therapeutic target for pain as well as a broad range of other conditions such as asthma or urge incontinence. The identification of resiniferatoxin as an ultrapotent ligand partially able to dissect the acute activation of TRPV1 from subsequent desensitization and the subsequent intense efforts in medicinal chemistry have revealed that TRPV1 affords a dramatic landscape of opportunities for pharmacological manipulation. While agonism and antagonism have represented the primary directions for drug development, the pharmacological complexity of TRPV1 affords additional opportunities. Partial agonism/partial antagonism, its modulation by signaling pathways, variable desensitization, and slow kinetics of action can all be exploited through drug design.
Export Options
About this article
Cite this article as:
M. Blumberg Peter, V. Pearce Larry and Lee Jeewoo, TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation, Current Topics in Medicinal Chemistry 2011; 11 (17) . https://dx.doi.org/10.2174/156802611796904825
DOI https://dx.doi.org/10.2174/156802611796904825 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Advantages of Using Synchrotron X-ray Based Techniques in Pediatric Research
Current Medicinal Chemistry The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Disorder in Milk Proteins: Structure, Functional Disorder, and Biocidal Potentials of Lactoperoxidase
Current Protein & Peptide Science Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Psoriasis in Children: A Review
Current Pediatric Reviews Eosinophilic Gastrointestinal Diseases in Children: A Practical Review
Current Pediatric Reviews Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update
Current Medicinal Chemistry Phytochemistry and Phytotherapeutic Aspects of <i>Elaeagnus angustifolia L.</i>
Current Drug Discovery Technologies New Therapeutic Targets and Drugs for the Treatment of Asthma
Mini-Reviews in Medicinal Chemistry Main Isoflavones Found in Dietary Sources as Natural Anti-inflammatory Agents
Current Drug Targets The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Potential Use of Dietary Natural Products, Especially Polyphenols, for Improving Type-1 Allergic Symptoms
Current Pharmaceutical Design Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Patent Selections
Recent Patents on Drug Delivery & Formulation Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Therapeutic Potentials of A2B Adenosine Receptor Ligands: Current Status and Perspectives
Current Pharmaceutical Design